BriaCell Therapeutics Corp. OTCQB: BCTXF JULY 2016 TSX-V: BCT - PowerPoint PPT Presentation

BriaCell Therapeutics Corp. OTCQB: BCTXF JULY 2016 TSX-V: BCT

Forward-Looking Statements Except for historical information, this presentation contains forward-looking statements, which reflect BriaCell’s current expectations regarding future events. These forward-looking statements involve known and unknown risks and uncertainties that could cause BriaCell’s actual results to differ materially from those statements. Those risks and uncertainties include, but are not limited to, our ability to access capital, the successful and timely completion of clinical trials, the receipt of all regulatory approvals and other risks detailed from time to time in our ongoing quarterly and annual filings. The forward-looking statements in this presentation are also based on a number of assumptions which may prove to be incorrect. Forward-looking statements contained in this presentation represent views only as of the date of this presentation and are presented for the purpose of assisting potential investors in understanding BriaCell’s business, and may not be appropriate for other purposes. BriaCell does not undertake to update forward-looking statements, whether written or oral, that may be made from time to time by or on its behalf, except as required under applicable securities legislation. Investors are cautioned not to rely on these forward-looking statements and are encouraged to read BriaCell’s continuous disclosure documents, including its financial statements which are available on SEDAR at www.sedar.com. 2

Investment Highlights  Leading Technology : Novel cancer immunotherapy  Right Timing : Initiating a Ph I/IIa clinical trial to validate the impressive safety and efficacy data of the two preliminary Ph I clinical trials  Unique Approach: Companion diagnostic co-development  Significant Market Potential : Multiple cancer indications. A multi-billion dollar target market.  Solid Management: Experts in immunotherapy, diagnostics, & corporate governance  Poised to Unlock Value: Significantly undervalued. Several short- and long-term milestones. Potential partnerships. 3

Cancer Immunotherapy BriaVax ™ (SV-BR-1-GM)  Breast cancer cell line  Allogeneic whole-cell vaccine secreting GM- CSF (“GVAX”).  Scalable production - grows as cancer cell line in RPMI + 10% FBS.  Irradiation prior to injection to prevent replication.  Used in combination with cyclophosphamide, and post-treatment with interferon- α.  Expected Result: Boosting the patient’s overall immune response to the tumor cells. Target Population  2 nd line use for late stage breast cancer .  Potential use for early stage cancers sharing antigen(s) of vaccine cells.  Potential use for non-breast cancers sharing antigen(s) of vaccine cells.  Maintenance therapy for duration of disease

BriaVax TM Development Story Dr. C. L. Wiseman (left) helped pioneer chemotherapies before they BriaVax TM is a proprietary were considered a possibility. breast cancer cell vaccine expressing GM-CSF Impressive safety and efficacy data in a , preliminary Phase I clinical trial Planning Phase I/IIa testing of BriaVax TM as 2 nd line treatment for metastatic breast cancer.

Clinical Data to-date First Phase I:  Used unmodified cell line + GM-CSF + cyclophosphamide  N = 14 late stage, treatment-refractory breast cancer patients  No significant adverse events, well tolerated  Median Overall Survival = 12.1 months Second Phase I:  Used GM-CSF-engineered cell line + cyclophosphamide + interferon- α  N = 4 late stage, treatment-refractory (3 breast cancer, and 1 ovarian cancer) patients  No significant adverse events, well tolerated  Median Overall Survival = 35 months  One robust responder with >90% regression during treatment , subsequent relapse (upon halting treatment) responded to re-treatment 6

Clinical Data to-date Second Phase I (using BriaVax TM ) 1 out of 4 Subjects responded with substantial tumor regression 7

Clinical Data to-date Lesion 1 Lesion 2 baseline 3 re-inoculations baseline 3 re-inoculations Lesion 3 baseline 3 re-inoculations 8

Hypothetical Mechanism of Action  Tumor regression in a patient was directly related to rising levels of CD40 Ligand (CD40L), a protein that is expressed on components of the immune system including activated T cells, B cells, platelets, monocytic cells, natural killer (NK) cells, mast cells, and basophils.  CD40L is known as one of the strongest stimulants of the immune system resulting in dendritic cell maturation, and rising serum levels of CD4+, CD8+, and NK cells, i.e., immune cells known for their anti-tumor activities. 9

Hypothetical Mechanism of Action Tumor Regression – Series-I Tumor Re-Regression – Series-II Baseline 3 Vaccines 6 Vaccines 3 Additional Vaccines Relapsed Before Treatment 6 Weeks Treatment 20 Weeks Treatment 8 Weeks CD40L Levels During Treatment CD40L Levels During Re-Treatment Series-I Series-II 4 months to restart of treatment 10

Hypothetical Mechanism of Action: CTA Analysis  Cancer Testis Antigens (CTAs): A class of cancer tissue specific antigens  PRAME: The CTA expressed in some breast cancers. The PRAME is also expressed in BriaVax ™.  BriaVax ™ injection may activate the patient T cells by PRAME recognition to cause tumor destruction. BriaVax ™ Normal Breast Cells HMEC** LUMINAL* BASAL* STROMAL* ERBB3+ ERBB3+ ERBB3- Nonclonogenic ALDH- ALDH+ ALDH- CEP55 PBK PLAC1 PRAME *Shehata et al. (2012). GEO DataSet GSE35399. 11 **Lowe et al. (2015). GEO DataSet GSE56718.

Hypothetical Mechanism of Action: HLA Analysis  BriaVax ™ caused a significant tumor shrinkage in one patient (Subject A002) - even at metastatic sites (Wiseman and Kharazi, Breast J 2006).  HLA analysis of BriaVax ™ and peripheral blood lymphocytes from the 4 patients showed that the special responder (subject A002) had the same Major Histocompatibility Complexes (MHCs) class I (HLA-A) and class II (HLA-DRB3) alleles as BriaVax ™. This double-match may explain BriaVax ™ ‘s strong tumor destruction activities in that subject. Survival Tumor Subject ID HLA-A HLA-B HLA-DRB3 (months) regression A001 40.7 No 02:01 24:02 13:02 41:01 03:01 - A002 33.7 Yes 02:01 11:01 18:03 44:02 02:02 - A003 35.6 No 02:01 03:01 07:02 13:02 Negative - B001 7.0 No 11:01 - 35:01 40:01 Negative - BriaVax N/A N/A 11:01 24:02 35:08 55:01 01:01 02:02 12

Hypothetical Mechanism of Action of BriaVax TM  BriaVax ™ expresses several genes known for their roles in immune cells, including HLA-A and HLA-DRB3.  BriaVax ™ may do one or few of the following: A. Directly act as antigen-presenting cells (APCs) B. Cross-Presentation: Dendritic cells may take up degraded BriaVax ™ and present BriaVax ™ antigens on their own MHCs to the patients T cells C. Cross-Dressing: Transfer BriaVax ™ antigens displayed on MHCs/HLAs to dendritic cells 13

Discovery of Gene Signature of BriaVax TM – Implications  BriaCell discovered a pair of biomarkers (HLA alleles) present in the top- responder and BriaVax TM but not in the 3 other clinical trial subjects  Implications: i. It improves our understanding of how the vaccine works, thus improving the likelihood of clinical success, and may accelerate the clinical development of BriaVax TM . ii. We plan to develop diagnostic tests to identify the top-responder (the patients for which the vaccine would work best) subgroup of patients.  We plan to further validate our discovery using the patients data in the upcoming Phase I/IIa study 14

Phase I/II Open Label Clinical Trial IND Cleared by FDA in Nov 2015:  Up to 24 stage-IV breast cancer patients  Primary objective : Safety & tumor response  Designed to amend the trial to evaluate: • Extending the dosing schedule (not limited to 6 vaccine injections) • Use in combination with other treatments • Application to earlier stage, more favorable to breast cancer patients • Application to other tumors 15

Accelerating the Clinical Development of BriaVax TM BriaDx ™ BriaVax ™ Combination therapy Companion diagnostics to boost efficacy: co-development Molecular analysis of Allogeneic tumor cell line blood and potentially + tumor samples GM-CSF secretion + Predict BriaVax ™ Cyclophosphamide responsiveness + Interferon- α Low development costs 16

Targeting a multi-billion dollar market FDA has allowed the testing of BriaVax TM for other cancer indications  Annual Potential Market (in Cancer Type Mortality (US) Million $US) at $100K/yr Breast 40,890 $4,089 at $100K/yr Annual Potential Market (in Cancer Type Mortality (US) Million $US) at $100K/yr Lung 158,080 $15,808 Ovary 14,240 $1,424 Prostate 26,120 $2,612 Bladder 16,390 $1,639 Pancreas 41,780 $4,178 Gastric 10,730 $1,073 Brain 16,050 $1,605 Total others (non breast) 324,280 $28,339 Total (breast & others) $32,428 Source: American Cancer Society Facts and Figures 2016 17

Upcoming Milestones Milestone Expected Timing Completion of manufacturing of BriaVax TM for Ph I/IIa trial 2H2016 Initiation of Ph I/IIa clinical trials of BriaVax TM 2H2016 Filing for additional patents 1H2017 Interim Data for Ph I/IIa trial 2H2017 Presentation of clinical data at a major conference 2H2017 Draft protocols for additional Ph II/III trials as counseled by FDA 2H2017 18